12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IDX184: Phase IIb ongoing

FDA lifted a partial clinical hold on IDX184 after reviewing interim data from 31 patients in a Phase IIb trial. The biotech now plans to enroll an additional 30 patients in the trial and begin a broad Phase IIb program with IDX184 in the...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >